N.D. Alves
University of Minho
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by N.D. Alves.
European Neuropsychopharmacology | 2018
J. Duarte; R. Gaspar; L. Caetano; P. Patrício; C. Cunha; A. Mateus-Pinheiro; N.D. Alves; A.R. Santos; S. Ferreira; V.M. Sardinha; João Filipe Oliveira; Nuno Sousa; Rodrigo A. Cunha; F. Ambrósio; Ana João Rodrigues; Luísa Pinto; C. Gomes
Microglia morphology is critical for brain functioning and undergoes profound remodeling in neuropsychiatric diseases. Rats prenatally exposed to glucocorticoids (iuDEX), which become anxious and have cognitive deficits at adulthood, exhibit gender-specific changes in microglia morphology in the medial pre-frontal cortex (mPFC), involved in anxiety pathophysiology [1]. Gender differences in microglia morphology, the higher prevalence of anxiety in women and the negative impact of anxiety in cognition, led us to specifically evaluate cognitive behaviour and associated circuits (mPFC-dorsal hippocampus, dHIP), as well as microglia morphology in female rats prenatally exposed to dexamethasone (1 mg/kg, subcutaneous injection to pregnant rats). Statistical analysis was performed in GraphPad Prism: Student’s t test was used to compare two independent means; differences were considered significant at p We report that iuDEX, besides anxious-like behavior, present deficits in recognition memory (SAL: 0.47±0.06, n=9; iuDEX: 0.21±0.03, n=10; p The chronic blockade of adenosine A2A receptors (A2AR), using a selective A2AR antagonist, SCH 58261 (0.1 mg/kg for 21 days before post-natal 90), which are core regulators of microglia morphology and physiology [1], ameliorated cognitive deficits (iuDEX + SCH: 0.35±0.02, n=7; iuDEX: 0.21±0.03, n=10; p=0.0304), but not anxiety-like behavior (iuDEX+SCH: 0.19±0.04, n=10; iuDEX: 0.20±0.04, n=7; p=0.9997), assessed by elevated plus maze test. Moreover, this treatment restored microglia morphology in the dHIP and reverted mPFC-dHIP desynchronization: delta (1-4 Hz; DEX+SCH: 0.59±0.08, n=10; p=0.3464 as compared with iuDEX), theta (4-12 Hz; DEX+SCH: 0.67±0.06, n=8; p=0.0366 as compared with iuDEX), beta (12-20 Hz; SAL: DEX+SCH: 0.61±0.05, n=10; p=0.7365, as compared with iuDEX) and low gamma (20-40 Hz; DEX+SCH: 0.52±0.06, n=10; p=0.4171 as compared with iuDEX). These results contrast with observations in the mPFC, where prenatal DEX induced microglia de-ramification, not reverted by blocking A2AR, which did not ameliorate anxiety [1]. Considering the role of microglia in shaping neuronal circuits, alterations in these cells during development may lead to an impairment in brain wiring, with implication in behaviour. Our results demonstrate microglia and adenosinergic system involvement in different components of mood disorders, namely anxiety and cognition.
European Neuropsychopharmacology | 2017
J. Correia; P. Patricio; N.D. Alves; A.R. Santos; M. Morais; A. Mateus-Pinheiro; S. Guerra-Gomes; V.M. Sardinha; G. Tavares; M. Martins; Nuno Sousa; L. Pinto; João Filipe Oliveira
.................................................................................................................................. VII Resumo .................................................................................................................................... IX Table of contents ...................................................................................................................... XI Abbreviations list ..................................................................................................................... XV
European Neuropsychopharmacology | 2016
P. Patricio; A. Mateus-Pinheiro; A.R. Machado-Santos; N.D. Alves; M. Morais; João Bessa; Nuno Sousa; L. Pinto
European Neuropsychopharmacology | 2017
E. Loureiro-Campos; N.D. Alves; A. Mateus-Pinheiro; P. Patricio; A.R. Machado-Santos; Nuno Sousa; L. Pinto
European Neuropsychopharmacology | 2017
N.D. Alves; P. Patricio; J. Correia; A. Mateus-Pinheiro; A.R. Machado-Santos; E. Loureiro-Campos; M. Morais; João Bessa; Nuno Sousa; L. Pinto
European Neuropsychopharmacology | 2017
E. Loureiro-Campos; N.D. Alves; A. Mateus-Pinheiro; P. Patricio; A.R. Machado-Santos; Nuno Sousa; L. Pinto
European Neuropsychopharmacology | 2016
M. Morais; J. Pereira; S. Aslani; P. Patricio; N.D. Alves; J. Correia; A.R. Machado-Santos; A. Mateus-Pinheiro; C. Portugal; L. Pinto; J. Palha; Nuno Sousa; João Bessa
European Neuropsychopharmacology | 2016
N.D. Alves; J. Correia; P. Patricio; A.R. Machado-Santos; A. Mateus-Pinheiro; E. Loureiro-Campos; M. Morais; João Bessa; Nuno Sousa; L. Pinto
European Neuropsychopharmacology | 2015
N.D. Alves; A.R. Machado-Santos; A. Mateus-Pinheiro; P. Patricio; J. Correia; M. Morais; João Bessa; Nuno Sousa; L. Pinto
European Neuropsychopharmacology | 2015
P. Patricio; A. Mateus-Pinheiro; A.R. Machado-Santos; N.D. Alves; M. Morais; João Bessa; Nuno Sousa; L. Pinto